A new study suggests that factor Xa inhibitors, such Eliquis™ apixaban from BMS and partner Pfizer, can be superior to warfarin. On a composite efficacy end-point in atrial fibrillation patients apixaban was significantly better than warfarin (1.3% versus 1.6%; p<0.01), … Continue reading